These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38692445)

  • 1. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials.
    Pamporis K; Karakasis P; Sagris M; Zarifis I; Bougioukas KI; Pagkalidou E; Milaras N; Samaras A; Theofilis P; Fragakis N; Tousoulis D; Xanthos T; Giannakoulas G
    Curr Probl Cardiol; 2024 Jul; 49(7):102615. PubMed ID: 38692445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
    Yang P; Shen W; Chen X; Zhu D; Xu X; Wu T; Xu G; Wu Q
    Heart Fail Rev; 2019 Sep; 24(5):637-646. PubMed ID: 31030322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials.
    Frankenstein L; Seide S; Täger T; Jensen K; Fröhlich H; Clark AL; Seiz M; Katus HA; Nee P; Uhlmann L; Naci H; Atar D
    Heart Fail Rev; 2020 Mar; 25(2):161-171. PubMed ID: 31364027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.
    Jhund PS; Talebi A; Henderson AD; Claggett BL; Vaduganathan M; Desai AS; Lam CSP; Pitt B; Senni M; Shah SJ; Voors AA; Zannad F; Solomon SD; McMurray JJV
    Lancet; 2024 Sep; 404(10458):1119-1131. PubMed ID: 39232490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.
    Serenelli M; Jackson A; Dewan P; Jhund PS; Petrie MC; Rossignol P; Campo G; Pitt B; Zannad F; Ferreira JP; McMurray JJV
    JACC Heart Fail; 2020 Mar; 8(3):188-198. PubMed ID: 31926854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
    Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
    Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis.
    Elshahat A; Mansour A; Ellabban M; Diaa A; Hassan A; Fawzy A; Saad OA; Abouelmagd M; Eid M; Elaraby A; Elkasaby MH; Abdelaziz A
    BMC Cardiovasc Disord; 2024 Sep; 24(1):489. PubMed ID: 39271992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review regarding the article 'Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a network meta-analysis of 32 randomized trials'.
    Wang L; Yuan D
    Curr Probl Cardiol; 2024 Aug; 49(8):102644. PubMed ID: 38750993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT.
    Ferreira JP; Rossello X; Eschalier R; McMurray JJV; Pocock S; Girerd N; Rossignol P; Pitt B; Zannad F
    JACC Heart Fail; 2019 Dec; 7(12):1012-1021. PubMed ID: 31779922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis.
    Berbenetz NM; Mrkobrada M
    BMC Cardiovasc Disord; 2016 Dec; 16(1):246. PubMed ID: 27905877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
    Hasegawa T; Nishiwaki H; Ota E; Levack WM; Noma H
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013109. PubMed ID: 33586138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
    Banerjee M; Maisnam I; Pal R; Mukhopadhyay S
    Eur Heart J; 2023 Oct; 44(37):3686-3696. PubMed ID: 37605637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
    Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
    Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.
    Quach K; Lvtvyn L; Baigent C; Bueti J; Garg AX; Hawley C; Haynes R; Manns B; Perkovic V; Rabbat CG; Wald R; Walsh M
    Am J Kidney Dis; 2016 Oct; 68(4):591-598. PubMed ID: 27265777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of mineralocorticoid receptor antagonists on new-onset or recurrent atrial fibrillation: a Bayesian and frequentist network meta-analysis of randomized trials.
    Karakasis P; Patoulias D; Popovic DS; Pamporis K; Theofilis P; Nasoufidou A; Stachteas P; Samaras A; Tzikas A; Giannakoulas G; Stavropoulos G; Kassimis G; Karamitsos T; Fragakis N
    Curr Probl Cardiol; 2024 Sep; 49(9):102742. PubMed ID: 39002620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events associated with early initiation of Eplerenone in patients hospitalized for acute heart failure.
    Kobayashi M; Yamashina A; Satomi K; Tezuka A; Ito S; Asakura M; Kitakaze M; Ferreira JP
    Int J Cardiol; 2024 Nov; 415():132477. PubMed ID: 39181408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.